ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

SKB107

A development code. Also written as “SKB107 for injection”.

Its studies are led by Sichuan Kelun Pharmaceutical.

Furthest: phase 1, since Jun 30, 20251 company-led study, 1 open or runningNext primary completion: Oct 1, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sichuan Kelun Pharmaceutical11 open or runningphase 1since Jun 30, 2025Jun 30, 2025Oct 1, 2027phase 1 · NCT07087197

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 30, 2025First study: phase 1 study in Metastatic Solid TumorsFirst studyNCT07087197 · 90 planned · China

Ahead

  1. Oct 1, 2027Primary completion: phase 1 study in Metastatic Solid TumorsNCT07087197

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07087197Metastatic Solid Tumors · China1RecruitingOct 1, 202790

How it is read

Names in the registry

  • “SKB107 for injection”, 1 entry

Codes read as this program: SKB107.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.